Triptorelin

Origin and Structure

Triptorelin is a synthetic decapeptide GnRH agonist developed in the late 1970s at Tulane University under Andrew Schally's laboratory — the same research program that isolated native GnRH. Substituting D-tryptophan for glycine at position 6 of the native sequence dramatically increased receptor affinity and metabolic stability, producing a compound roughly 100-fold more potent than endogenous GnRH.

Triptorelin is marketed as Decapeptyl in Europe (Ipsen, launched in the 1980s) and as Trelstar in the United States, where it was FDA-approved in 2000 for advanced prostate cancer. Gonapeptyl is another European brand. Formulations include monthly, 3-month, and 6-month depot intramuscular injections using microsphere or suspension technology.

Mechanism of Action

Triptorelin binds the GnRH receptor on pituitary gonadotrophs with high affinity. Unlike native gonadorelin, which is delivered in brief pulses and supports physiological gonadotropin secretion, triptorelin's long-acting depot delivery produces continuous receptor occupancy. This continuous exposure initially stimulates a surge of LH and FSH — the clinically important "testosterone flare" — followed within 2–4 weeks by profound receptor downregulation and desensitization.

The result is pharmacological hypogonadism: serum testosterone falls to castrate levels in men, and estrogen falls to postmenopausal levels in women. This is the same mechanism exploited by nafarelin, leuprolide, and goserelin, differing primarily in route of administration and duration.

Clinical Evidence and Indications

Triptorelin has a mature, well-replicated evidence base across several indications:

• Advanced/metastatic prostate cancer. The core approved indication. Androgen deprivation with triptorelin produces durable PSA and tumor response, and it is a standard first-line hormonal therapy often combined with antiandrogens or newer agents like abiraterone and enzalutamide.
• Central precocious puberty in children, where arresting premature HPG activation preserves adult height and addresses psychosocial concerns.
• Endometriosis, typically as a 3–6 month course to suppress endometrial tissue activity.
• Uterine fibroids and pre-IVF pituitary suppression, as part of structured assisted-reproduction protocols.

Among the GnRH agonist class, choice between triptorelin, leuprolide, and goserelin is usually driven by formulation preference, cost, and local practice rather than differences in efficacy.

Practical Considerations

Triptorelin is administered intramuscularly as a depot — 3.75 mg monthly, 11.25 mg every three months, or 22.5 mg every six months, depending on the formulation. The testosterone flare during the first two weeks can transiently worsen prostate cancer symptoms and is typically managed by co-administering a non-steroidal antiandrogen (bicalutamide or flutamide) for the first 2–4 weeks of therapy.

For men on androgen deprivation therapy, side-effect management — bone density, cardiovascular risk, metabolic changes — is a significant part of ongoing care. Patients on long-term GnRH agonist therapy typically receive DEXA scans, lipid monitoring, and frequently bone-protective therapy.

Safety and Regulatory Status

The side-effect profile is predictable from the pharmacology and centers on hypogonadal symptoms: hot flashes, decreased libido, erectile dysfunction, mood changes, fatigue, and loss of bone mineral density. Longer-term androgen deprivation is associated with increased cardiovascular risk, insulin resistance, and sarcopenia — active research areas with guideline-level management recommendations from oncology and urology societies.

Injection-site reactions and, rarely, pituitary apoplexy in patients with undiagnosed pituitary adenomas are notable labeled risks. Triptorelin is contraindicated in pregnancy. It is FDA-approved, on the WHO Essential Medicines List, and standard-of-care across its indications.

The Bottom Line

Triptorelin is a legitimate, well-characterized oncology and gynecology drug — not a lifestyle peptide. It is the counterpart to gonadorelin: same receptor, opposite clinical effect, driven entirely by dosing pattern. For anyone studying GnRH pharmacology, the gonadorelin/triptorelin contrast is one of the clearest illustrations in endocrinology of how exposure kinetics rather than molecule identity can invert a drug's effect.